Communiqués de presse Archive - Page 14 of 21 - Ose Immunotherapeutics - Société de biotechnologie intégrée qui développe des immunothérapies innovantes
Communiqués de presse Archive - Page 14 of 21 - Ose Immunotherapeutics - Société de biotechnologie intégrée qui développe des immunothérapies innovantes
  • Our Company
    • Presentation
    • Management Team
    • Board of directors
    • Scientific Advisory Board
    • Contact
  • Products
    • Tedopi®
    • OSE-279
    • Lusvertikimab (OSE-127)
    • Pegrizeprument (FR104)
    • BI 770371
    • ABBV-230
    • CLEC-1
  • Research & Development
    • Scientific publications
  • Investors
    • Press Releases
    • Regulated information
    • Financial documents
    • General Shareholders’ meetings
  • Partnerships
    • Pharma partnerships
    • Clinical partnerships
    • Academic and public Partnerships
  • News
    • Agenda
    • Press Releases
  • Contact
en
  • fr

P
r
o
j
e
c
t
s
A
r
c
h
i
v
e
s

October 2021

OSE Immunotherapeutics and the FoRT Foundation Announce Initiation of a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Opdivo®

October 2021

OSE Immunotherapeutics Announces Dosing of the First Healthy Volunteer in Phase 1 Clinical Trial of CoVepiT

October 2021

OSE Immunotherapeutics and Boehringer Ingelheim Present Positive Phase 1 Results with BI 765063

October 2021

OSE Immunotherapeutics Announces €10.7 Million in Additional Public Funding, via Bpifrance

October 2021

OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement for FR 104

October 2021

OSE Immunotherapeutics Announces First Peer-Reviewed Publication in Science Advances on OSE-230

October 2021

OSE Immunotherapeutics Receives Authorization for Phase 1 Clinical Trial of CoVepiT

October 2021

OSE Immunotherapeutics Reports 2020 Financial Results

October 2021

OSE Immunotherapeutics and ARCAGY – GINECO Announce Initiation of a Randomized Phase 2 Clinical Trial

October 2021

OSE Immunotherapeutics to Present New Data at AACR 2021

  • Précédent
  • 1
  • …
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • …
  • 21
  • Suivant

Head Office

22, boulevard Benoni Goulin
44200 Nantes – France

Tel : +33 (0)2 28 29 10 10

Email : contact@ose-immuno.com

Paris Office

10, place de Catalogne
75014 Paris – France

Tel : +33 (0)1 43 29 78 57

Fax : +33 (0)1 42 03 04 16

Our Company
Products
Investors
Agenda
Research & Development
Partnerships
Press Releases
Follow us
©2021 ose-immuno
Financial documents
Legal information and Personal data protection policy
Site internet créé par Adveris